Our organization, together with an international consortium of partners, has submitted the project TB-SHIELD-WOMEN – Supportive nutritional Health Intervention for Enhanced recovery and Lowered Drug toxicity in vulnerable groups of Women with tuberculosis under the call Call: HORIZON-JU-GH-EDCTP3-2026-01-TB-01-two-stage: Global collaboration action for the development of TB drugs for therapy and chemoprophylaxis in adults and children in sub-Saharan Africa, focused on global collaboration for the development and optimisation of tuberculosis therapies.

TB-SHIELD project logo.
TB-SHIELD project logo.

The project aims to improve tuberculosis treatment outcomes among vulnerable women in sub-Saharan Africa, particularly those affected by malnutrition, HIV, pregnancy, or postpartum conditions. The proposal includes a multicountry Phase II clinical trial in Uganda, Ethiopia, and the Democratic Republic of Congo to evaluate whether targeted nutritional support can enhance recovery, reduce drug toxicity, and improve the safety of current TB treatments.

The consortium brings together partners from Europe and Africa, including Karolinska Institutet (Sweden), R-Evolution Worldwide, Addis Ababa University (Ethiopia), Makerere University (Uganda), and the Institut National de Recherche Biomédicale (DR Congo), combining expertise in infectious diseases, nutrition, and clinical research.

The project has been submitted to the Global Health EDCTP3 Joint Undertaking programme, which supports international research collaborations to fight infectious diseases in sub-Saharan Africa.

Leave a Reply

Your email address will not be published. Required fields are marked *

Explore More

PRECISION-asympTB – Proposal submitted to EDCTP3 call for innovative TB treatment research in sub-Saharan Africa

PRECISION-asympTB was submitted under the EDCTP3 2026 Call on Tuberculosis.  Despite decades of global efforts, TB remains one of the leading infectious causes of death worldwide. One of the greatest challenges today

Biomedical Ethics and Regulatory Capacity Building: International Dialogues

The LiberHetica and BERC-Luso consortia will meet on the 26th March 2021 to discuss about Biomedical Ethics and Regulatory Capacity Building in Sub-Saharan African countries. The LiberHetica and BERC-Luso are two projects funded by

NeuroSolve project obtained the Clinical Trial Ethical Approval in Zambia too!

After receiving the ethical approval in Tanzania, NeuroSolve obtained the ethical clearance in Zambia too. The ethical clearance certificate will allow to conduct medical research on Neurocysticercosis also in Zambia.